Response to Azacytidine in a Patient With Refractory Peripheral T-cell Lymphoma With TET2 Mutation.
Publication/Presentation Date
7-1-2024
Abstract
Peripheral T-cell lymphomas (PTCLs) are an aggressive form of non-Hodgkin lymphomas. PTCLs have multiple subtypes, with PTCL not otherwise specified (PTCL-NOS) being the most common. This subtype usually has a high rate of relapse. Making an accurate diagnosis requires molecular genetic analyses, histopathological examination, and immunophenotyping. Treatment for PTCL traditionally starts with the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone). We present a case of a patient with PTCL-NOS who progressed despite multiple treatment regimens, including both traditional and novel therapeutic agents, and finally achieved good results with azacytidine, selected based on a
Volume
16
Issue
7
First Page
65416
Last Page
65416
ISSN
2168-8184
Published In/Presented At
Le, M. A., Al-Moussally, F., & Carilli, A. (2024). Response to Azacytidine in a Patient With Refractory Peripheral T-cell Lymphoma With TET2 Mutation. Cureus, 16(7), e65416. https://doi.org/10.7759/cureus.65416
Disciplines
Medicine and Health Sciences
PubMedID
39184618
Department(s)
Department of Medicine
Document Type
Article